RxDoctor Payments Data

Ronan Lev, MD

Urology · Saint Peters, MONPI 1871602573

Payments from drug & device makers

$7,841in general payments, 2019–2025

Across 186 payments — averaging $42.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Neotract Inc.$1K
  • Boston Scientific$516
  • Astellas Pharma US Inc$468
  • Sumitomo Pharma America, Inc.$390
  • Ferring Pharmaceuticals Inc.$367
  • plus $3K from 30 others

What the payments were for

  • Travel & lodging$1,29717%
  • Food & beverage$6,54483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,841 in reported general payments places this provider in the 70th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$166,505
Medicare patients
521
Services billed
3,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron151$90,972
OrgovyxRelugolix24$63,748
GemtesaVibegron19$14,342
Tamsulosin Hcl495$5,467
Trospium Chloride103$2,664
Solifenacin Succinate30$1,913
Finasteride136$1,555
Trospium Chloride ErTrospium Chloride21$1,301
Oxybutynin Chloride47$741
Alfuzosin Hcl ErAlfuzosin Hcl48$611
Oxybutynin Chloride ErOxybutynin Chloride34$296
Dutasteride22$232
NitrofurantoinNitrofurantoin Macrocrystal13$186
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim41$183
Tramadol Hcl24$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$468$90,972151 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$390$78,09043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 urology providers in Missouri.

Other urology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →